Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
4.350
+0.320 (7.94%)
Dec 20, 2024, 4:00 PM EST - Market closed

Fulcrum Therapeutics Revenue

Fulcrum Therapeutics had revenue of $80.87M in the twelve months ending September 30, 2024, up 2,987.86% year-over-year. In the year 2023, Fulcrum Therapeutics had annual revenue of $2.81M, down -55.77%.

Revenue (ttm)
$80.87M
Revenue Growth
+2,987.86%
P/S Ratio
3.34
Revenue / Employee
$1,064,092
Employees
76
Market Cap
234.63M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.81M-3.54M-55.77%
Dec 31, 20226.34M-12.82M-66.90%
Dec 31, 202119.16M10.34M117.19%
Dec 31, 20208.82M--
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Aurora Cannabis 219.84M
biote 193.06M
LifeMD 193.06M
BGM Group 29.87M
Profound Medical 8.98M
Ocugen 4.70M
Precigen 3.96M
Cardiff Oncology 688.00K
Revenue Rankings